Modality
Gene Therapy
MOA
PD-L1i
Target
MDM2
Pathway
Epigenetic
Migraine
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
May 2019
→ Nov 2031
Phase 2Current
NCT03698315
279 pts·Migraine
2019-05→2031-11·Not yet recruiting
279 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-265.7y awayPh3 Readout· Migraine
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Not yet…
Catalysts
Ph3 Readout
2031-11-26 · 5.7y away
Migraine
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03698315 | Phase 2/3 | Migraine | Not yet recr... | 279 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 |